{
  "docId": "019de077-58c2-77ec-8b05-6d27c4bb0498",
  "docSlug": "35a6e53e15f172ec3a7e4b1f473eaa42",
  "documentTitle": "Genprex | Investor Presentation Deck | 58 slides",
  "authorId": "genprex",
  "authorName": "Genprex",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 27,
  "pageCount": 58,
  "prevPage": 26,
  "nextPage": 28,
  "slideType": "traction",
  "function": "show_traction",
  "density": "balanced",
  "nDataPoints": 16,
  "notes": "The slide shows four separate bar charts comparing Control, Atezo (Tecentriq), REQORSA, and Combination therapies across four immune cell types.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-58c2-77ec-8b05-6d27c4bb0498/27",
  "deckHref": "/decks/019de077-58c2-77ec-8b05-6d27c4bb0498",
  "deckJsonHref": "/decks/019de077-58c2-77ec-8b05-6d27c4bb0498.json",
  "deckAnchorHref": "/decks/019de077-58c2-77ec-8b05-6d27c4bb0498#slide-27",
  "components": [
    {
      "bbox": {
        "h": 0.7,
        "w": 0.47,
        "x": 0.23,
        "y": 0.23
      },
      "kind": "chart",
      "text": "Four bar charts showing immune cell percentages",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2b1d8373-ff7d-4f71-b2b5-179a2fdc0cd8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.25,
        "x": 0.73,
        "y": 0.81
      },
      "kind": "paragraph",
      "text": "Atezolizumab (Atezo) is the generic name of Tecentriq. huNK = human natural killer cells. DC = dendritic cells. MDSC = myeloid derived suppressor cells. TME = tumor microenvironment",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5a21b757-2da6-4f35-81fc-cd9053ee9f2c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.6,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "Increased Immune Response with Reqorsa® and Tecentriq",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dc3e3536-f7c6-46c3-915c-06c9375e1fc3",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Chartjunk Elimination",
      "slug": "chartjunk-elimination",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "4ec2905a-6c89-4dad-8d26-ee13f236cebd",
      "evidence": "Four bar charts showing immune cell percentages",
      "confidence": 0.7
    },
    {
      "name": "Visual Anchors",
      "slug": "visual-anchors",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "541697a9-62bf-450a-aa77-7e0089eba0d7",
      "evidence": "Four bar charts showing immune cell percentages",
      "confidence": 0.5
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 40,
      "from": 21,
      "beatId": "fba14042-e1cc-44ad-974d-c9a2c1f21ee2",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Visualization",
      "beatSlug": "monroes-sequence-visualization",
      "evidence": "Future vision and potential impact of Genprex's gene therapies",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}